Los Angeles Capital Management
AVBP icon

Los Angeles Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Los Angeles Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$399K Sell
17,308
-22,992
-57% -$519K ﹤0.01% 943
2025
Q4 		$744K Buy
+40,300
New +$839K ﹤0.01% 751

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Los Angeles Capital Management's AVBP Position: Q1 2026 in Review

Los Angeles Capital Management reduced its ArriVent BioPharma (AVBP) stake by 57% in Q1 2026, selling an estimated $519K and leaving 17,308 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #943.

Los Angeles Capital Management first reported a position in AVBP in Q4 2025 and has held it in 2 quarters since. The position peaked at $744K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Los Angeles Capital Management held 17,308 shares of ArriVent BioPharma worth $399K as of Q1 2026.
  • Los Angeles Capital Management sold 22,992 ArriVent BioPharma shares in Q1 2026, an estimated $519K.
  • ArriVent BioPharma made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #943 holding.
  • Los Angeles Capital Management first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 2 quarters since.
  • Los Angeles Capital Management's ArriVent BioPharma position peaked at $744K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.